References
- Petrikova J, Lazurova I. Ovarian failure and polycystic ovary syndrome. Autoimmun Rev 2012;11:A471–8
- Luborsky J. Ovarian autoimmune disease and ovarian autoantibodies. J Womens Health Gend Based Med 2002;11:585–99
- Alper MM, Garner PR. Premature ovarian failure: its relationship to autoimmune disease. Obstet Gynecol 1985;66:27–30
- Betterle C, Rossi A, Dalla Pria S, et al. Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol (Oxf) 1993;39:35–43
- Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99
- Belvisi L, Bombelli F, Sironi L, Doldi N. Organ-specific autoimmunity in patients with premature ovarian failure. J Endocrinol Invest 1993;16:889–92
- Goswami R, Marwaha RK, Goswami D, et al. Prevalence of thyroid autoimmunity in sporadic idiopathic hypoparathyroidism in comparison to type 1 diabetes and premature ovarian failure. J Clin Endocrinol Metab 2006;91:4256–9
- Coccia ME, Rizzello F. Ovarian reserve. Ann N Y Acad Sci 2008;1127:27–30
- Jirge PR. Ovarian reserve tests. J Hum Reprod Sci 2011;4:108–13
- de Vet A, Laven JS, de Jong FH, et al. Anti-Mullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357–62
- van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum anti-Mullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979–87
- Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 2011;20:1193–7
- Aikawa NE, Sallum AM, Pereira RM, et al. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol 2012;30:445–9
- Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013;98:3785–92
- Mok CC, Chan PT, To CH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum 2013;65:206–10
- Clowse ME, Copland SC, Hsieh TC, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2011;63:1777–81
- Brouwer J, Laven JS, Hazes JM, et al. Levels of serum anti-Mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:1534–8
- Poppe K, Velkeniers B, Glinoer D. Thyroid disease and female reproduction. Clin Endocrinol (Oxf) 2007;66:309–21
- Petrikova J, Lazurova I, Yehuda S. Polycystic ovary syndrome and autoimmunity. Eur J Intern Med 2010;21:369–71
- Kachuei M, Jafari F, Kachuei A, Keshteli AH. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2012;285:853–6
- Garelli S, Masiero S, Plebani M, et al. High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013;169:248–51
- Ganie MA, Marwaha RK, Aggarwal R, Singh S. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. Eur J Endocrinol 2010;162:1117–22